| Literature DB >> 25950011 |
Milin Shah1, Vatsal Shah1, Anasuya Ghosh1, Zheng Zhang2, Tamara Minko1.
Abstract
Drugs with low aqueous solubility and permeability possess substantial challenges in designing effective and safe formulations. Synergistic solubility and permeability enhancement in a simple formulation can increase bioavailability and efficacy of such drugs. To overcome limitations of the clinical formulation of Taxol®, Paclitaxel (PTX) was reformulated with various β-cyclodextrin (CD) derivatives suitable for parenteral administration. Results indicated that β-CDs can efficiently form complexes with PTX at lower molar ratios, enhance aqueous solubility up to 500 times and improved cellular internalization of PTX. All β-CD derivatives were found to be safe as excipient since none showed detectable signs of cyto-genotoxicity. As a result, the CD-PTX complexes significantly increased the cytotoxicity of the drug. The study concluded that CD-PTX formulations could substitute the current intravenous infusion of PTX obviating the use of non-inert excipient Cremophor EL.Entities:
Keywords: Compounds; Cyclodextrins; Enhancement; Inclusion; Permeability enhancement; Preformulation; Solubility
Year: 2015 PMID: 25950011 PMCID: PMC4418459 DOI: 10.13188/2327-204X.1000011
Source DB: PubMed Journal: J Pharm Pharmacol (Los Angel)